ProfoundBio (Suzhou) Co., Ltd. announced that it has received $112 million in a round of funding led by new investor Ally Bridge Group on February 13, 2024. The transaction included participation from new investors Nextech Invest Ltd., RA Capital Management, L.P., OrbiMed Advisors LLC, Surveyor Capital Management, Piper Heartland Healthcare Capital, LLC, LifeSci Venture Partners, Janus Henderson Investors, Medicxi, Logos Capital, Octagon Capital, accounts advised by T. Rowe Price Group, Inc., returning investors Lyfe Capital, Eli Lilly Investment Consulting (Shanghai) Co., Ltd. Andrew Lam, Eric Dobmeier and Enoch Kariuki will join board of directors of the company. This funding round was over-subscribed.